What are the leading stocks listed on 2023 Pharmaceuticals?
Innovative medicine refers to new drugs with independent intellectual property rights, safe and effective, with international competitiveness, is the core driving force of the pharmaceutical industry. The following editorial about the pharmaceutical listed companies leading stocks have, we take a look at it, hope to bring reference.
What are the leading stocks of listed pharmaceutical companies
The leading stocks of listed pharmaceutical companies are Tencent Holdings Limited, Yemin Biotechnology, China Biopharmaceuticals.
1, Tencent Holdings Limited (00700.HK): Tencent's pharmaceutical subsidiary Tencent Healthcare is one of China's leading Internet healthcare platforms, and is one of the leading companies in the pharmaceutical industry.
2. WuXi Biologics (02269.HK): a biopharmaceutical company focusing on innovative drug development, is one of the largest drug development outsourcing service providers in China.
3, WuXi Biologics (02269.HK): a biopharmaceutical company focusing on innovative drug R&D and is one of the largest drug R&D outsourcing service providers in China.
Most Potential Leading Biopharmaceutical Stocks
Potential leading biopharmaceutical stocks are as follows:
1. Hengrui Medicine (600276), the first share of the domestic innovative drugs. The main product lines are anti-tumor, anesthesia, contrast agents and so on. The company's return on net assets for many years to maintain more than 23%, net profit for many years to maintain a rate of growth of more than 20%. The company's R&D strength is very strong, the management team is relatively good, and the sales capacity is also very strong.
2. Aier Ophthalmology (300015), the first share of domestic ophthalmic hospital chain. Mainly to provide patients with a variety of ophthalmic diseases diagnosis, treatment and medical optometry and other ophthalmic medical services. The company's return on net assets for many years to maintain at about 20%, net profit for many years to maintain a rate of growth of more than 30%.
3. Myriad Medical (300760), the first domestic medical equipment. The main product lines are life and information support, in vitro diagnostics, medical imaging and so on. The company's return on net assets for many years to maintain more than 25%, net profit for many years to maintain a rate of growth of more than 25%.
Biomedical top ten leading stocks
One, Hengrui Medicine (600276), the first domestic innovative drugs. The main product lines are anti-tumor, anesthesia, contrast agents and so on. The company's net
return on assets for many years to maintain more than 23%, net profit for many years to maintain a rate of growth of more than 20%. The company's R&D strength is very strong,
the management team is relatively good, and the sales ability is also very strong.
Two, Aier Ophthalmology (300015), the first share of domestic ophthalmic hospital chain. Mainly to provide patients with a variety of ophthalmic diseases diagnosis, treatment
and medical optometry and other ophthalmic medical services. The company's return on net assets for many years to maintain at about 20%, net profit for many years to maintain 30%
more than the rate of growth. The company's business model is relatively excellent, and its operating ability and brand reputation continue to strengthen.
Three, Myriad Medical (300760), the first domestic medical equipment. The main product lines are life and information support, in vitro diagnostics, medical
imaging and so on. The company's return on net assets for many years to maintain more than 25%, net profit for many years to maintain a rate of growth of more than 25%. The company as
complete globalization layout of the leading medical devices, high-end, platform steadily advancing, the position is very solid, the long-term space is huge.
Four, Changchun High-tech (000661), the first domestic biopharmaceutical stocks. The main product lines are growth hormone, syncytial virus vaccine. The company
the return on net assets for many years to maintain more than 16%, net profit for many years to maintain a rate of growth of more than 30%. As a leading biomedical
pharmaceutical company in China, the company's performance has exceeded the expected growth.
Fifth, WuXi AppTec (603259), the first share of domestic medical research and development services. The main business is the discovery of small molecule chemical drugs, research and development and production
production of a full range of integrated platform services. The company's return on net assets has remained above 20% for many years, and its net profit has maintained a growth rate of over 25% for many years
. The company is the world's leading pharmaceutical R & D service platform, market space is broad, performance is expected to maintain rapid growth.
Six, Tigermed (300347), the country's leading clinical contract research organization (CRO) leader. The main business is for pharmaceutical product development
Provide Ⅰ to Ⅳ phase clinical trial technical services, data management and other clinical research services. The company's return on net assets has improved to around 17% in the past two years
and its net profit has maintained a growth rate of over 56% for many years.
Seven, I Wu biology (300357), the first domestic desensitization diagnosis and treatment shares. The company's dust mite drops to maintain high growth, the heavyweight product Huanghua
Artemisia pollen sublingual drops into the site verification, is expected to be approved for listing in 2020. The company's return on net assets has remained above 21% for many years
and its net profit has maintained a growth rate of over 25% for many years. The company as China's only sublingual desensitization leading enterprises, the competitive landscape
extremely good, market share of more than 80%, the company's long-term growth potential.
Eight, Tongze medical (600763), the first domestic oral chain shares. The company through the "hospital can be copied + doctors can be copied + team can be copied"
model, to start the layout of the dental hospital chain. The company's return on net assets has been maintained at about 23% for many years, and the net profit has been maintained at 50% for many years
right growth rate. China's oral market space is vast, the company is expected to be
fast development under the two major trends of population aging and consumption upgrading.
Nine, Anto Bio (603658), the domestic IVD leading stocks. The company is mainly engaged in the in vitro diagnostic reagents and its supporting instrumentation research and development, production
and sales. The company's return on net assets for many years to maintain at about 30%, net profit for many years to maintain a rate of growth of more than 25%. Chemical hair
Light industry will enter the era of differentiation. The company with 70% biological raw material assets, mainstream projects, assembly lines and other advantages, is expected to continue to replace
foreign and other domestic products, to maintain sustained growth.
Ten, Hualan Bio (002007), the leading stock of domestic blood products. The company's main product lines are blood products and vaccine products. The company's
return on net assets for many years to maintain at about 19%, net profit for many years to maintain a rate of growth of about 30%. With the slow
slow recovery of the domestic blood products industry and the continued release of influenza vaccines, the company's performance is expected to be further improved.
What are the leading innovative drug stocks
1, Hesco: the leading
In the second quarter of 2022 Hesco's main business is APIs and patented technologies, parenteral nutrition system, anesthesia products, etc., with revenues of 332 million yuan, 291 million yuan, 129 million yuan, or 26.58%%, 23.3%%, 10.34%%.
The financial report shows that in the third quarter of 2022, the company's operating income of 849 million yuan; net profit attributable to listed shareholders of 33,229,100 yuan; fully diluted return on net assets of 1.17%; gross profit margin of 66.33%, earnings per share of 0.03 yuan.
2, Baiji Shenzhou: leading
2022 the second quarter of Baiji Shenzhou company's main business for BRUKINSA / Baiyueze, Baizean, technology licensing, R & D services and intellectual property licensing revenue, revenue of 1.514 billion yuan, 1.251 billion yuan, 534 million yuan, accounting for 35.97%%, 29.72%%, 12.69%%.
The financial report shows that in the third quarter of 2022, the company's operating income of 2.659 billion yuan; net profit attributable to listed shareholders of -3.77 billion yuan; fully diluted return on net assets of -10.97%; gross profit margin of 80.84%, earnings per share -2.81 yuan.
3, Xinlitai: leading
2022 the second quarter of Xinlitai company's main business for the preparation, raw materials, devices, etc., revenues of 1.463 billion yuan, 134 million yuan, 50,141,500 yuan, accounting for 87.71%%, 8.01%%, 3.01%%.
The financial report shows that in the third quarter of 2022, the company's operating income of 880 million yuan; net profit attributable to listed shareholders of 191 million yuan; fully diluted return on net assets of 2.47%; gross profit margin of 72.68%, earnings per share of 0.18 yuan.
4, Hengrui medicine: leading
2021 fourth quarter of Hengrui medicine company's main business for the anti-tumor, anesthesia, contrast agents, etc., revenues of 13.072 billion yuan, 4.916 billion yuan, 3.27 billion yuan, accounting for 50.46%%, 18.98%%, 12.62%%.
Hengrui Medicine released its Q3 2022 financial results, realizing operating income of 5.717 billion yuan, up -17.16% year-on-year, and net profit of 1.054 billion yuan, up -31.54% year-on-year; earnings per share was 0.17 yuan.
Innovative drug concept stocks which listed companies
1, WuXi Kande (603259): the company is mainly engaged in pharmaceutical R & D services. December 27 opening news, WuXi Kande latest offer 78.940 yuan, up 1.58%, 3 days the share price rose 2.43%; this year, the rise fell - 37.83%, P/E ratio of 45.11.
2, Zhifei biological (300122): the company is engaged in the vaccine, biological products, research and development, production and sales.December 27 opening news, Zhifei biological 3 days within the share price rose 2.48%, the latest quoted at 87.580 yuan, turnover of 1.172 billion yuan.
3, Tigermed (300347): the company is mainly engaged in professional clinical research services. December 27 opening news, Tigermed's latest offer of 102.900 yuan, the latest share price rose 5.23% in 3 days, the price-earnings ratio of 31.09.
4, Huadong Pharmaceuticals (000963): the company is engaged in the production of pharmaceutical industry and pharmaceutical commercial distribution. December 27 news, Huadong Pharmaceuticals (000963): the company is engaged in the production of pharmaceutical industry and pharmaceutical commercial distribution. On December 27th, East China Pharmaceutical's share price rose 6.74% in 7 days, as of the close of the stock at 46.620 yuan, up 6.76%, with a total market capitalization of 81.771 billion yuan.
5, Kanglong Huacheng (300759): the company is engaged in small molecule drug research and development services. December 27 news, Kanglong Huacheng 5 days within the share price rose 9.45%, the latest at 64.310 yuan, volume of 11,057,200 lots, the total market value of 76.598 billion yuan.
6, Changchun High-tech (000661): the company's business has a biopharmaceutical and proprietary Chinese medicine research and development, production and sales. December 27 opening news, Changchun High-tech the latest offer of 171.900 yuan, 3 days within the share price rose 0.89%, the price-earnings ratio of 18.52.
7, Shanghai Pharmaceuticals (601607): the company's main business for the pharmaceutical R & D and manufacturing, distribution and retail. Manufacturing, distribution and retail. December 27 opening news, Shanghai Pharmaceuticals latest report 18.150 yuan, down 3.82%. Volume of 29,231,800 lots, total market capitalization of 67.09 billion yuan.
8, Watson biological (300142): the company's business human vaccines and other biotechnology drugs set of research and development, production and sales. December 27 opening news, Watson biological latest offer 39.020 yuan, the stock price fell 2.46% in 3 days, the price-earnings ratio of 143.09.
9, Ealing Pharmaceutical (002603): the company is mainly engaged in drug R & D, production and sales. December 27 opening update, Ealing Pharmaceuticals rose 37.42% this year, as of 15:00, the stock fell 7.69% at 32.520 yuan.